AU2009239906A1 - 5-methyl-1-(naphthalen-2-yl)-1H-pyrazoles useful as sigma receptor inhibitors - Google Patents

5-methyl-1-(naphthalen-2-yl)-1H-pyrazoles useful as sigma receptor inhibitors Download PDF

Info

Publication number
AU2009239906A1
AU2009239906A1 AU2009239906A AU2009239906A AU2009239906A1 AU 2009239906 A1 AU2009239906 A1 AU 2009239906A1 AU 2009239906 A AU2009239906 A AU 2009239906A AU 2009239906 A AU2009239906 A AU 2009239906A AU 2009239906 A1 AU2009239906 A1 AU 2009239906A1
Authority
AU
Australia
Prior art keywords
formula
compound
methyl
pyrazol
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2009239906A
Other languages
English (en)
Inventor
Maria Magdalena Bordas Gelabert
Maria Rosa Cuberes-Altisent
Maria Jose Pretel Sanchez
Antoni Torrens Jover
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esteve Pharmaceuticals SA
Original Assignee
Laboratorios del Dr Esteve SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios del Dr Esteve SA filed Critical Laboratorios del Dr Esteve SA
Publication of AU2009239906A1 publication Critical patent/AU2009239906A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2009239906A 2008-04-25 2009-04-27 5-methyl-1-(naphthalen-2-yl)-1H-pyrazoles useful as sigma receptor inhibitors Abandoned AU2009239906A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08384005.8 2008-04-25
EP08384005A EP2113501A1 (en) 2008-04-25 2008-04-25 5-Methyl-1-(naphthalen-2-YL)-1H-Pyrazoles useful as sigma receptor inhibitors
PCT/EP2009/055065 WO2009130331A1 (en) 2008-04-25 2009-04-27 5-methyl-1-(naphthalen-2-yl)-1h-pyrazoles useful as sigma receptor inhibitors

Publications (1)

Publication Number Publication Date
AU2009239906A1 true AU2009239906A1 (en) 2009-10-29

Family

ID=39739580

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009239906A Abandoned AU2009239906A1 (en) 2008-04-25 2009-04-27 5-methyl-1-(naphthalen-2-yl)-1H-pyrazoles useful as sigma receptor inhibitors

Country Status (11)

Country Link
US (1) US8492425B2 (https=)
EP (2) EP2113501A1 (https=)
JP (1) JP2011518811A (https=)
KR (1) KR20110006697A (https=)
CN (1) CN102066333A (https=)
AU (1) AU2009239906A1 (https=)
BR (1) BRPI0910679A2 (https=)
CA (1) CA2722256A1 (https=)
MX (1) MX2010011674A (https=)
RU (1) RU2010147918A (https=)
WO (1) WO2009130331A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
EP2361904A1 (en) * 2010-02-04 2011-08-31 Laboratorios Del. Dr. Esteve, S.A. 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride and crystalline forms thereof
BR112012012456A2 (pt) * 2009-11-25 2020-08-11 Laboratorios Del Dr. Esteve, S.A. sal de 4-[2-[[5-metil-1-(2-naftalenil)-1h-pirazol-3-il]oxi]etil]morfolina,processo para a preparação do sal de cloridrato, composição farmacêutica e sal de cloridrato
SG10201500832PA (en) * 2010-02-04 2015-04-29 Esteve Labor Dr 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride polymorphs and solvates
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
EP2353598A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for use in the prevention and/or treatment of postoperative pain
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
EP2395003A1 (en) 2010-05-27 2011-12-14 Laboratorios Del. Dr. Esteve, S.A. Pyrazole compounds as sigma receptor inhibitors
EP2418192A1 (en) * 2010-07-30 2012-02-15 Esteve Química, S.A. Intermediates for the preparation of 1-aryl-pyrazol-3-one compounds useful as sigma receptors inhibitors
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
EP2426111A1 (en) * 2010-08-09 2012-03-07 Laboratorios Del. Dr. Esteve, S.A. 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms
EP2460804A1 (en) * 2010-12-03 2012-06-06 Laboratorios Del Dr. Esteve, S.A. 5-methyl-1-(naphthalen-2-yl)-1h-pyrazole derivatives and their use in potentiating the effect of opioid analgesics
EP2460519A1 (en) * 2010-12-03 2012-06-06 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in bone cancer pain
EP2524694A1 (en) * 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
EP2818166A1 (en) * 2013-06-26 2014-12-31 Laboratorios del Dr. Esteve S.A. Use of sigma receptor ligands for the prevention and treatment of pain associated to interstitial cystitis/bladder pain syndrome (IC/BPS)
TW201607538A (zh) 2013-12-17 2016-03-01 以斯提夫博士實驗室股份有限公司 血清素－去甲腎上腺素再攝取抑制劑（ＳＮＲＩＳ）和σ受體配體組合物
EP3174612B1 (en) 2014-08-01 2019-09-04 Smart Billiard Lighting LLC Billiard table lighting and game play monitor
MA41177A (fr) * 2014-12-15 2017-10-24 Esteve Labor Dr Utilisation de ligands des récepteurs sigma dans l'arthrose
US12345406B2 (en) 2022-02-09 2025-07-01 Blake Martin Interactive LED system for enhancing billiard gameplay

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9824310D0 (en) 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
EP1634872A1 (en) * 2004-08-27 2006-03-15 Laboratorios Del Dr. Esteve, S.A. Pyrazole derivatives as sigma receptor inhibitors
CA2576144C (en) 2004-08-27 2012-12-11 Laboratorios Del Dr. Esteve, S.A. Sigma receptor inhibitors
EP1829875A1 (en) * 2006-03-01 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Pyrazole derivatives as sigma receptor inhibitors
MX2008011016A (es) 2006-03-01 2008-09-08 Esteve Labor Dr Inhibidores de receptor sigma.

Also Published As

Publication number Publication date
EP2285781A1 (en) 2011-02-23
CA2722256A1 (en) 2009-10-29
US8492425B2 (en) 2013-07-23
KR20110006697A (ko) 2011-01-20
RU2010147918A (ru) 2012-05-27
MX2010011674A (es) 2010-11-25
US20110118253A1 (en) 2011-05-19
BRPI0910679A2 (pt) 2015-09-29
CN102066333A (zh) 2011-05-18
WO2009130331A1 (en) 2009-10-29
JP2011518811A (ja) 2011-06-30
EP2113501A1 (en) 2009-11-04

Similar Documents

Publication Publication Date Title
US8492425B2 (en) 5-methyl-1-(naphthalen-2-yl)-1H-pyrazoles useful as sigma receptor inhibitors
CN105658655B (zh) 作为CFTR调节剂的噻吩并[2,3-c]吡喃
CA2576144C (en) Sigma receptor inhibitors
US8202872B2 (en) Pyrazole derivatives as sigma receptor inhibitors
CA2708022C (en) Tricyclic triazolic compounds
FI92584C (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten pyridatsiiniamiinijohdannaisten valmistamiseksi
CN101621998B (zh) 具有取代的杂环基团的苯并咪唑大麻素激动剂
JP2025522631A (ja) Ｐｒｍｔ５阻害剤及びその使用
DE69428142T2 (de) Quinolin- oder Quinazolinderivate, deren Herstellung und Verwendung
IE900069L (en) 2-aminopyrimidinone derivatives
IL178882A (en) Tetrahydronaphthyridine derivatives useful as histamine h3 receptor ligands
EP1713797A1 (en) 1-ISOPROPYL-2-OXO-1,2-DIHYDROPYRIDINE-3-CARBOXAMIDE DERIVATIVES HAVING 5-HT sb 4 /sb RECEPTOR AGONISTIC ACTIVITY
CA2129146A1 (en) Imidazole, triazole and tetrazole derivatives
WO2008087529A1 (en) Nicotinic acetylcholine receptor modulators
CN103003267A (zh) 西格玛受体抑制剂
AU2009239889B2 (en) Process for the preparation of naphthalen-2-yl-pyrazol-3-one intermediates useful in the synthesis of sigma receptor inhibitors
JP5455130B2 (ja) 複素環式誘導体
FI94049C (fi) Menetelmä terapeuttisesti käyttökelpoisten N-(3-hydroksi-4-piperidinyyli)bentsamidien valmistamiseksi
KR20080067355A (ko) 염증 치료에 유용한 피라졸
WO2006056848A1 (en) Octahydropyrrolo[3,4-c]pyrrole derivatives
DE60319254T2 (de) Pyrazolamide zur behandlung von hiv-infektionen
KR20080032206A (ko) Ｃｂ１ 조절제로서의 피라졸 유도체
EP1829875A1 (en) Pyrazole derivatives as sigma receptor inhibitors
KR0145705B1 (ko) 항 고혈압성 3-피페리디닐-인다졸 유도체
JP2014118357A (ja) 置換ピラゾロピリミジン化合物、及びその合成中間体の製法

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application